Print

Ingrid Schwarzenberger, new Chair of the IGBA Biosimilars Committee

June 13 2017 - IGBA is pleased to announce today the nomination of Ingrid Schwarzenberger, Head Global Regulatory Affairs at Sandoz Biopharmaceuticals, as the new Chair of the IGBA Biosimilars Committee. Ingrid has played a leading role in the establishment of a regulatory framework for biosimilar medicines in Europe through her 15 years of experience with the Biosimilar Medicines Group, a Medicines for Europe sector group. Ingrid has a wealth of international regulatory knowledge and business and scientific experience.

Read More

 

 

 

 

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site